Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenamiprofen is a non-steroidal anti-inflammatory drug (NSAID) of the propionic acid derivative class, developed and manufactured by Dalian Tianyu Pharmaceutical. It functions by inhibiting the cyclooxygenase enzymes, COX-1 and COX-2, which are responsible for the conversion of arachidonic acid to prostaglandins. By reducing prostaglandin levels, fenamiprofen exerts analgesic, anti-inflammatory, and antipyretic effects. It is primarily utilized for the relief of moderate to severe pain associated with conditions such as postoperative recovery, oncology, physical trauma, low back pain, gout, and neuralgia, as well as acute pain from renal and urinary calculi.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fenamiprofen.